Immuneed appoints Annick de Vries as new Chief Scientific Officer
May 27, 2026
Uppsala, Sweden – May 27, 2026
Immuneed AB, a specialized preclinical service provider and pioneer in human whole blood analysis, today announced the appointment of Dr. Annick de Vries as Chief Scientific Officer (CSO). Dr. de Vries joins the executive leadership team as CSO while continuing her role on Immuneed’s Scientific Advisory Board, reflecting her long-standing and deepening commitment to the company’s scientific direction.
Dr. de Vries is a life science leader with more than 20 years of experience spanning target validation, preclinical studies, and regulated bioanalysis. She previously served as Chief Scientific Officer at Sanquin Diagnostic Services, where she built and led a bioanalysis team supporting large protein assays, immune monitoring, and global diagnostic services (ISO15189/IVDR). She is a recognized key opinion leader (KOL) in therapeutic drug monitoring (TDM) of biologics and has co-authored over 200 peer-reviewed publications, including more than 100 focused on PK/ADA assays for biologics.
Dr. de Vries holds a Ph.D. in pharmacology from Utrecht University and conducted postdoctoral research on immune–neural cross-talk at the Universities of Bristol, Edinburgh, and Leuven. She subsequently led biomarker assay development at the Translational Medicine Research Collaboration (Pfizer).
‘’Annick joining as CSO marks an important step in building the leadership team that Immuneed needs to grow. What excites me most is not just the depth of her scientific background – it is the energy and the network she brings. In a field where credibility and connections open doors, having Annick in our corner makes a real difference. Her expertise will be invaluable as we work to establish ID.Flow® as a recognized New Approach Methodology, bringing human-relevant immunotoxicology testing to the forefront of drug development’’ – Alexander Kele, CEO, Immuneed
“Immuneed is all about what truly matters to me – a platform that has the potential to change how the industry thinks about preclinical safety and efficacy testing. ID.Flow® is not just a clever assay; it is a fundamentally more human-relevant way of asking the right questions before a drug ever reaches a patient. I have watched this team build something remarkable, and I am proud to be joining them at this exciting stage.” – Annick de Vries, CSO, Immuneed
About Immuneed
Immuneed is a specialized services provider that, through its innovative ID.Flow® platform, offers drug developers physiologically relevant immunological assessments for preclinical- stage molecules. ID.Flow® proudly aligns with the latest regulatory guidance, the New Approach Methodologies, and supports the 3Rs by reducing the number of animals used in research. By utilizing fresh human blood, our expert team conducts comprehensive studies to analyze how a drug affects both the adaptive and innate immune responses, all from a single sampling. By interpreting the results, Immuneed provides relevant data to drug developers, assisting with IND filings and enhancing the safety and effectiveness of drug development in the preclinical stage.
Contact details for inquiries
To know more about our offering, visit us at www.immuneed.com or contact us at contact@immuneed.com
For investment-related opportunities, please contact us at investment@immuneed.com